Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion

Next Previous
X
Search
Trial Profile

Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Retinal oedema; Retinal vein occlusion
  • Focus Registrational; Therapeutic Use
  • Acronyms RVO3
  • Sponsors Allergan

    • Most Recent Events

    • 01 Jan 2018 Primary endpoint of Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity in the Study Eye has been met, according to results published in the Graefes Archive for Clinical and Experimental Ophthalmology.
    • 01 Jan 2018 Results published in the Graefes Archive for Clinical and Experimental Ophthalmology
    • 21 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top